Intra-Cellular Therapies Is On Fire [Seeking Alpha]
Intra-Cellular Therapies Inc. (ITCI)
Last intra-cellular therapies inc. earnings: 3/2 07:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.intracellulartherapies.com/investor-relations
Company Research
Source: Seeking Alpha
The company is seeking FDA approval to expand CAPLYTA's use to treat Major Depressive Disorder. CAPLYTA's growing acceptance contributed to a 50% YoY increase in revenue for Intra-Cellular Therapies in Q4 2023. Investment Thesis Intra-Cellular Therapies ( NASDAQ: ITCI ) flagship drug is getting a lot of love from US doctors. In 2023, the number of psychiatrists prescribing CAPLYTA, a drug used for treating schizophrenia and bipolar depression 'BD,' jumped 63%, reaching a total of 36,000 physicians. That's a lot, especially when you think about how there are only 59,000 psychiatrists in the US. Here's the kicker. The growth of prescriptions outpaced that of prescribers in 2023 (85% vs 63%). This means that not only more doctors are prescribing CAPLYTA, but those already prescribing it are doing so more frequently. This is like getting a two-for-one deal on growth for 2024. But that's not all. Through CAPLYTA, which is already a hit in schizophrenia and bipolar depression, ITCI
Show less
Read more
Impact Snapshot
Event Time:
ITCI
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ITCI alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ITCI alerts
High impacting Intra-Cellular Therapies Inc. news events
Weekly update
A roundup of the hottest topics
ITCI
News
- Will Intra-Cellular Therapies (ITCI) Report Negative Q1 Earnings? What You Should Know [Yahoo! Finance]Yahoo! Finance
- Intra-Cellular Therapies Announces Closing of $575 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares [Yahoo! Finance]Yahoo! Finance
- Intra-Cellular Therapies Announces Closing of $575 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional SharesGlobeNewswire
- Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $120.00 price target on the stock.MarketBeat
- Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) had its price target raised by analysts at Canaccord Genuity Group Inc. from $100.00 to $107.00. They now have a "buy" rating on the stock.MarketBeat
ITCI
Earnings
- 2/22/24 - Beat
ITCI
Sec Filings
- 4/25/24 - Form 4
- 4/24/24 - Form 8-K
- 4/18/24 - Form 8-K
- ITCI's page on the SEC website